SBIR Phase I: Development of novel dendrimer-based technologies for phosphorylation analyses

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$150,000.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1113085
Agency Tracking Number:
1113085
Solicitation Year:
2010
Solicitation Topic Code:
BC
Solicitation Number:
n/a
Small Business Information
Tymora
1281 Win Hentschel Blvd., West Lafayette, IN, 47906-4182
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
965433258
Principal Investigator:
Anton Iliuk
(765) 490-6834
anton.iliuk@tymora-analytical.com
Business Contact:
Anton Iliuk
(765) 490-6834
anton.iliuk@tymora-analytical.com
Research Institution:
Stub




Abstract
This Small Business Innovation Research (SBIR) Phase I project addresses the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology to be developed during this Phase I project will greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective inhibitor screenings, kinase/phosphatase activity quantitation, and efficient phosphopeptide e ichment for proteomic experiments. The broader/commercial impacts of this research are the development of platform technology to improve a set of biochemical assays, and help the discovery of new therapeutic targets. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R & D), responsible for over 30% of the total drug discovery expenses. These R & D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government